TransOMIC Launches transEDIT-dual CRISPR Combinatorial Gene Knockout Kits

HUNTSVILLE, Ala., April 26, 2017 /PRNewswire/ -- The simultaneous knockout of two genes can help identify functional relationships between genes, which can lead to a better understanding of biological systems and can have direct implications for cancer therapeutic development as well as other therapeutic advancements.

The transEDIT-dual CRISPR arrayed library targets over 19,000 genes in the Human genome. The vector system used for constructing the CRISPR arrayed library (pCLIP-dual) was engineered to express two different gRNAs targeting the same gene from one lentiviral vector.

transOMIC technologies now offers the pCLIP-dual vector system for combinatorial knockouts, where one vector expresses two gRNAs, each targeting a separate gene.

The transEDIT-dual CRISPR system was developed in collaboration with Dr. Greg Hannon of Cold Spring Harbor Laboratory and Cancer Research UK and Dr. Simon Knott of Cedars-Sinai, using a new algorithm that creates novel and superior gRNA sequences targeting the human genome.

"Our transEDIT-dual CRISPR products give researchers a superior set of genome-editing tools. These tools speed up the pace of our understanding of complex biological pathways, which helps to rapidly identify key therapeutic targets," said Blake Simmons, CEO of transOMIC technologies. "We expect the transEDIT-dual CRISPR arrayed library and our new combinatorial gene knockout kits to take our customers' research further, faster."

More information about the transEDIT-dual CRISPR arrayed library and combinatorial knockout kits can be found at

About transOMIC: Since 2012, transOMIC has been providing the international scientific community with research products that help unravel genetic complexity and give insight into gene function, ultimately providing biological understanding of disease and possibilities for therapeutics.We have an extensive offering of gene-based products to enable research scientists to perform genome editing, gene knockdown, and gene over-expression studies. Our leading-edge products are developed through ongoing collaborations with academic thought leaders.

CONTACT: Blake Simmons, 1-256-327-9513,

To view the original version on PR Newswire, visit:

SOURCE transOMIC technologies

Back to news